Merck KGaA
Three-sector diversified operating company: (1) Life Science sells consumables/reagents, bioprocessing (Process Solutions), lab products and services to biopharma & academia; (2) Healthcare develops and markets prescription drugs (oncology, neurology/MS, fertility, rare disease); (3) Electronics supplies specialty materials for semiconductor fabs and displays. Razor/razor-blade recurring consumables in Life Science + Electronics; patent-cliff pharma economics in Healthcare. Growth via secular tailwinds + serial M&A (Millipore, Sigma-Aldrich, Versum, SpringWorks, pending Bio-Techne).
Earnings, margins, COGS & capex
FY2025 net sales EUR21.1B (organic +3.1%, reported -0.3% as a ~-3.7% FX drag offset organic growth), EBITDA-pre EUR6.1B (organic +5.6%, margin 28.9%), EPS-pre EUR8.34. Three roughly comparable sectors: Life Science ~EUR8.9B (42% of sales), Healthcare ~EUR8.6B (41%, +3.7% organic), Electronics ~EUR3.6B (17%, -0.6% organic). Q1 2026 beat (revenue EUR5.134B, EBITDA-pre EUR1.530B) driven by Process Solutions/bioprocessing recovery (+16%) and AI-driven semiconductor materials, offsetting Healthcare weakness from US Mavenclad generics; management raised FY2026 guidance after the beat.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~40¢ is cost of goods and ~31¢ operating expense, leaving ~29¢ of operating profit (~1¢ net).
Revenue trend
Margins
resilient; organic EBITDA-pre +5.6% FY2025 despite FX
pressured by SpringWorks acquisition integration/financing; FY2026 guided EUR7.10-8.00
conservative pre-Bio-Techne; will rise on the ~$11.3B deal close
COGS structure
Not separately disclosed in retrieved sources. Structurally: Life Science and Electronics are consumables/specialty-materials businesses with high recurring gross margin; Healthcare carries pharma COGS plus heavy R&D. FX and input/energy costs (German/EU manufacturing base) are the main variable-cost sensitivities; a ~-3.7% FX effect was the dominant FY2025 reported-vs-organic gap.
Capex
Capacity-investment phase: Merck is expanding bioprocessing (Process Solutions) and semiconductor-materials capacity to meet novel-modality and AI-compute demand. Exact FY2025 capex not confirmed in retrieved sources; historically elevated (~8-10% of sales). Plus large inorganic capital deployment — >$35B in M&A since 2000 (Millipore, Sigma-Aldrich, Versum, SpringWorks $3.9B in 2025), and the pending ~$11.3B all-cash Bio-Techne acquisition ($73/share, ~36% premium; announced 25-06-2026, expected close late-2026/early-2027).
Latest earnings
Beat — revenue EUR5.134B above expectations, EBITDA-pre EUR1.530B; shares rose ~6% on the print
FY2026 guidance RAISED after Q1: group sales EUR20.4-21.4B and EBITDA-pre EUR5.7-6.1B (up from the FY2025-issued EUR20.0-21.1B / EUR5.5-6.0B). FY2026 EPS-pre range EUR7.10-8.00. Guidance assumes NO US Mavenclad sales from March 2026 (generic competition) and excludes any upside from a potential US Pergoveris launch
- Q1 2026 revenue
- EUR5.134B (-2.8% reported, +2.9% organic)
- Q1 2026 EBITDA-pre
- EUR1.530B (-0.3% reported, +5.3% organic)
- Q1 2026 operating cash flow
- EUR818M (+47% YoY)
- Process Solutions Q1 growth
- +16% organic
Growth drivers
- Process Solutions / bioprocessing recovery — Life Science's engine returned to double-digit organic growth (+16% Q1 2026) as biopharma destocking ended; secular demand from novel modalities (biologics, cell & gene therapy)
- Semiconductor Solutions in Electronics — specialty materials for advanced/AI logic and memory nodes; a direct pick-and-shovel play on the AI capex cycle (+4% organic Q1 2026)
- Rare Diseases in Healthcare — SpringWorks (nirogacestat/Ogsiveo) acquisition adds a rare-disease oncology franchise to offset MS/Mavenclad erosion
- Bio-Techne acquisition (pending) — ~$11.3B deal adds proteins, antibodies, reagents and analytical/diagnostics tools, deepening the Life Science moat
- Management targets these three focus areas (Process Solutions, Rare Diseases, Semiconductor Solutions) to drive up to ~80% of medium-term growth
Bull & bear
A rare three-sector compounder buying the dip in its own best business: bioprocessing has troughed and is re-accelerating (+16% Q1), AI is pulling semiconductor materials, and the Bio-Techne deal deepens the highest-quality Life Science franchise — all while the stock trades at a conglomerate discount to pure-play tools peers.
- Process Solutions inflected back to double-digit organic growth in Q1 2026 (first >EUR1B quarter since Q1 2023), signaling the bioprocessing destocking cycle is over and a multi-year recovery is underway
- Electronics is a credible, under-appreciated AI pick-and-shovel — Merck supplies specialty materials into advanced-node and AI-memory ramps with recurring, per-wafer economics
- Bio-Techne (~$11.3B) and SpringWorks ($3.9B) show the family owners deploying capital counter-cyclically into secular winners at scale — the same playbook that turned Millipore/Sigma-Aldrich into today's crown jewel
- Management RAISED FY2026 guidance after Q1 despite baking in zero US Mavenclad and zero Pergoveris upside — the base case is conservative
- Diversification means the Healthcare patent cliff is absorbable: Life Science + Electronics (~59% of sales) are both accelerating into it
- Trades at a discount to single-sector comps (Thermo Fisher, Sartorius, Entegris) despite owning assets in all three of their markets — a re-rating or eventual break-up optionality exists
A financial-engineering story fighting a real pharma patent cliff with an expensive, leverage-adding acquisition — reported revenue was flat, EPS is guided DOWN, and every sector faces a larger, more focused pure-play competitor while China and FX add tail risk.
- FY2026 EPS-pre is guided to EUR7.10-8.00, DOWN from EUR8.34 — the company is not growing earnings per share right now, and reported revenue was roughly flat (-0.3%) in 2025
- The Mavenclad US generic hit is real and immediate, and Healthcare's pipeline is thin versus large-cap pharma — the SpringWorks rare-disease bet has to work to fill the gap
- Bio-Techne's ~$11.3B all-cash price is rich (its largest deal since Sigma-Aldrich) and pushes leverage up materially; integration/synergy risk on top of still-digesting SpringWorks
- Bioprocessing recovery could stall — one strong quarter doesn't prove a durable up-cycle, and biopharma capex is macro-sensitive
- In every business Merck faces a bigger, more focused competitor: Thermo Fisher/Danaher in tools, Entegris/DuPont in materials, big pharma in drugs — perpetual margin and share pressure
- Conglomerate structure invites a persistent valuation discount and offers no obvious near-term catalyst to close it; FX translation keeps masking whatever organic strength exists
- China exposure (semiconductor materials export controls, tools localization) is a structural overhang on two of three sectors
What it is worth
Public-market comps + sum-of-the-parts. Market cap ~EUR63B (~$72B) at ~EUR146/share (late-June 2026), plus ~EUR8.6B net debt (pre-Bio-Techne) for ~EUR72B EV against ~EUR6.1B EBITDA-pre (~12x EV/EBITDA-pre); ~17-18x trailing EPS-pre (EUR8.34), richer on lower reported EPS.
Mavenclad erosion plus a stalled bioprocessing recovery and a leverage-heavy, dilutive Bio-Techne deal keep EPS flat-to-down; the conglomerate discount persists or widens, capping the stock near or below the current level.
Mid-single-digit organic growth with EBITDA-pre recovering toward the top of the EUR5.7-6.1B FY2026 raised range; stock compounds with earnings once EPS re-inflects in 2027, holding roughly the current multiple.
Bioprocessing up-cycle proves durable, AI-materials compound, Bio-Techne integrates accretively and the conglomerate discount narrows toward pure-play tools multiples — supports a re-rating well above the current ~EUR63B cap.
The core debate is a conglomerate discount: Merck owns Life Science (deserving Thermo Fisher/Sartorius-like premium multiples), Electronics (Entegris-like materials multiple) and Healthcare (a pharma multiple discounted for the patent cliff). A sum-of-parts arguably exceeds the blended trading multiple — the discount is the price of complexity and the near-term EPS decline. Re-rating hinges on (a) durable bioprocessing recovery, (b) accretive Bio-Techne integration, and (c) Healthcare stabilizing post-Mavenclad. Not financial advice; illustrative ranges only.
SWOT
Strengths
- Genuine diversification across three large, secularly-growing science markets (life-science tools, pharma, electronic materials) — few peers span all three, smoothing any single-sector cycle
- Deep recurring-consumables base in Life Science and Electronics (reagents, media, filters, specialty chemistries) with high switching costs and validated-supplier lock-in
- Proven serial-M&A integration engine (Millipore, Sigma-Aldrich, Versum) that has repeatedly re-platformed the company toward higher-quality earnings
- Direct leverage to two of the strongest secular tailwinds in the economy: biologics/novel modalities and AI-driven semiconductor demand
- Family-controlled (E. Merck KG) governance enabling long-horizon capital allocation and large countercyclical acquisitions
Weaknesses
- Healthcare pharma pipeline thinner and more patent-exposed than large-cap pharma peers — Mavenclad (MS) faces US generics from 2026, a direct near-term earnings hole
- Large EUR reporting base creates persistent FX translation drag when the USD weakens (~-3.7% FY2025), obscuring healthy organic growth in reported numbers
- Rising leverage — the ~$11.3B all-cash Bio-Techne deal on top of SpringWorks pushes net debt/EBITDA up from a conservative ~1.4x and consumes financing capacity
- Bioprocessing is cyclical — the 2023-24 biopharma destocking cut showed how quickly Process Solutions can swing; recovery durability is not guaranteed
- Complexity/conglomerate discount — three unrelated sectors are harder for the market to value than pure-plays like Thermo Fisher or Entegris
Opportunities
- Bioprocessing super-cycle — cell & gene therapy, GLP-1 biologics scale-up and biosimilars all expand Process Solutions TAM
- AI semiconductor materials — advanced-node and high-bandwidth-memory ramp is a multi-year specialty-materials growth vector where Merck is an incumbent supplier
- Bio-Techne integration — proteomics, antibodies and spatial-biology tools cross-sell into Merck's existing life-science customer base
- Rare-disease oncology expansion off the SpringWorks platform (nirogacestat, mirdametinib) with pipeline label extensions
- Onshoring/supply-chain-security demand for Western-sourced semiconductor and bioprocessing materials as customers de-risk from single-region supply
Threats
- US Mavenclad generic erosion from March 2026 — a known, guided earnings headwind in Healthcare
- Bioprocessing demand re-softening if biopharma capex tightens or destocking returns
- Intense, well-capitalized competition in every sector (Thermo Fisher, Danaher, Sartorius in tools; Entegris, DuPont, JSR in materials; big pharma in drugs)
- China/geopolitics — semiconductor-materials export controls and China biopharma/tools localization could pressure Electronics and Life Science demand
- FX and European energy/manufacturing-cost inflation weighing on reported margins
- Integration and financing risk on the Bio-Techne deal (regulatory approval, purchase-price discipline, leverage)
Moats, dependencies & bottlenecks
Moats
Reagents, cell-culture media and filtration are written into biopharma manufacturing filings; requalifying a supplier is costly and slow, giving Merck sticky, recurring, high-margin revenue.
Co-developed, fab-qualified chemistries for advanced nodes; qualification cycles are long and per-wafer economics recur, but competition (Entegris, DuPont, JSR, Shin-Etsu) is intense.
Millipore + Sigma-Aldrich created one of the broadest reagent/consumables catalogs; Bio-Techne would extend it into proteins/antibodies/proteomics. Breadth itself is a moat (one-stop validated supplier).
E. Merck KG control enables large countercyclical M&A and patient reinvestment that a quarter-driven board might avoid — a structural, if intangible, advantage.
Real but time-limited and eroding — Mavenclad faces US generics from 2026; the moat here is narrower and shorter-dated than the tools/materials moats.
Dependencies
Demand / end-market Process Solutions swings with biopharma production and inventory cycles — the 2023-24 destocking cut demonstrated the sensitivity.
Demand / end-market Electronics tracks fab utilization and advanced-node/HBM ramps; a semiconductor downturn hits materials volumes.
Large USD revenue reported in EUR — a weaker USD created a ~-3.7% FY2025 reported drag despite organic growth.
~$11.3B deal expected to close late-2026/early-2027; antitrust, shareholder approval and financing execution are gating.
Geopolitical / regulatory Semiconductor-materials export controls and China biopharma/tools localization could constrain Electronics and Life Science demand.
Product / pipeline With Mavenclad eroding, near-term Healthcare growth leans on rare-disease assets (nirogacestat) delivering.
Advantages
- Only major player with scaled, incumbent positions across life-science tools, pharma, AND electronic materials simultaneously
- Recurring consumables/specialty-materials revenue with high switching costs in two of three sectors
- Direct, dual exposure to the two dominant secular tailwinds (biologics + AI compute)
- Family-owner governance enabling large countercyclical, long-horizon capital deployment
- Proven M&A integration track record (Millipore, Sigma-Aldrich, Versum) de-risking the Bio-Techne thesis
Weaknesses
- EPS guided down for 2026; reported revenue roughly flat (-0.3%) — no current per-share earnings growth
- Healthcare is the weakest leg: eroding patents, thinner pipeline, generic-exposed
- Leverage rising from an expensive acquisition on top of an unfinished one
- Every sector faces a larger, more focused pure-play competitor
- Conglomerate/complexity discount with no obvious near-term catalyst to close it
Bottlenecks
- Pharma patent cliff (Mavenclad US generics from 2026) with a pipeline thinner than large-cap pharma peers
- Rising leverage from back-to-back large cash deals (SpringWorks + pending Bio-Techne) constraining further M&A firepower near-term
- FX translation persistently masking organic performance in reported EUR numbers
- Bioprocessing recovery durability unproven after only one strong quarter
- No pure-play focus — conglomerate structure invites a valuation discount and diffuses management attention across three unrelated markets
Top signals & trends
Top signals
Management lifted FY2026 sales (to EUR20.4-21.4B) and EBITDA-pre (to EUR5.7-6.1B) ranges despite conservatively assuming zero US Mavenclad and zero Pergoveris upside.
Strongest single tell that the bioprocessing destocking cycle has ended and the highest-margin Life Science engine is re-accelerating.
Strategic deepening of the Life Science moat, but a rich price ($73/share, ~36% premium) that raises leverage and adds integration risk — bullish long-term, cautionary near-term.
Mavenclad erosion + financing costs mean no per-share earnings growth this year.
Validates the under-appreciated AI-materials thesis as a growth vector independent of the drug business.
Trends
Cell & gene therapy, GLP-1 biologics and biosimilar scale-up expand Process Solutions TAM; destocking has ended.
Advanced-node and high-bandwidth-memory ramps pull specialty electronic materials — a multi-year Electronics tailwind.
Mavenclad US genericization is the immediate example; ongoing risk across the Healthcare portfolio.
Customers de-risking from single-region supply favor Merck's Western manufacturing footprint in both tools and materials.
Could constrain Electronics and Life Science demand in China and complicate advanced-materials shipments.
Merck is an active consolidator (Bio-Techne) in a scale-advantaged, breadth-rewarding market.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Specialty & fine chemical feedstock suppliers Raw chemistries and reagents feeding Life Science and Electronics manufacturing; energy/input-cost sensitive (EU base).
Contract manufacturers / packaging / logistics Supporting a global consumables and specialty-materials supply chain.
Lonza, Samsung Biologics, large-cap pharma) Buy bioprocessing consumables, media, filters and reagents for drug production — core Process Solutions demand.
Consume Merck Electronics specialty materials per-wafer at advanced/AI nodes.
Academic & government research labs and diagnostics Buy Life Science reagents, antibodies and lab products (expanded by Bio-Techne).
The dominant life-science tools/bioprocessing scale leader — Merck's primary Life Science competitor and the pure-play benchmark for valuation.
Bioprocessing (Cytiva) and diagnostics powerhouse competing head-on with Merck Life Science / Process Solutions.
German bioprocessing pure-play (Frankfurt-listed) directly competing in filtration, single-use and cell-culture — closest bioprocessing comp.
Specialty semiconductor materials/purification — a leading pure-play competitor to Merck Electronics on advanced-node materials.
Electronics & semiconductor materials competitor (advanced chemistries, CMP, lithography materials).
Analytical instruments and lab tools overlapping Merck Life Science; also a comp for the Bio-Techne analytics assets.
Lab/production materials and distribution competing in Life Science consumables and services.
Proteins/antibodies/reagents peer — being ACQUIRED by Merck KGaA (~$11.3B, pending); competitor turning into an owned asset.
Large-cap pharma competing with Merck Healthcare in oncology, neurology/MS (Biogen in MS vs Mavenclad) and specialty drugs.